Patient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments

References

• AIHW. Impact of Overweight and Obesity as a Risk Factor for Chronic Conditions: Australian Burden of Disease Study. Canberra: AIHW; 2017.
   Google Scholar
• World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization Technical Report Series. 2000;i–xii, 1–253.
   Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–S138. doi:10.1161/01.cir.0000437739.71477.ee
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity and overweight; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed November, 2021.
   Google Scholar
• Australian Institute of Health and Welfare (AIHW). Overweight and Obesity in Australia: A Birth Cohort Analysis. Canberra: AIHW; 2017.
   Google Scholar
• AIHW. Overweight and obesity: an interactive insight: Australian government; 2021. Available from: https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity-an-interactive-insight/contents/what-is-overweight-and-obesity. Accessed February 13, 2024.
   Google Scholar
• Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. doi:10.1186/1471-2458-9-88
   PubMed Web of Science ®Google Scholar
• Gadde KM, Atkins KD. The limits and challenges of antiobesity pharmacotherapy. Expert Opin Pharm. 2020;21(11):1319–1328. doi:10.1080/14656566.2020.1748599
   PubMed Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA. 2016;315(22):2424–2434. doi:10.1001/jama.2016.7602
   PubMed Web of Science ®Google Scholar
• Huq S, Todkar S, Lahiri SW. Patient perspectives on obesity management: need for greater discussion of BMI and weight-loss options beyond diet and exercise, especially in patients with diabetes. Endocr Pract. 2020;26(5):471–483. doi:10.4158/EP-2019-0452
   PubMed Web of Science ®Google Scholar
• Patterson L, Kee F, Hughes C, O’Reilly D. The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study. BMC Public Health. 2014;14:87.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Rigas G, Williams K, Sumithran P, et al. Delays in healthcare consultations about obesity - barriers and implications. Obes Res Clin Pract. 2020;14(5):487–490. doi:10.1016/j.orcp.2020.08.003
   PubMed Web of Science ®Google Scholar
• Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmaco Economic. 2014;32(9):883–902.
   PubMed Web of Science ®Google Scholar
• Merlo G, van Driel M, Hall L. Systematic review and validity assessment of methods used in discrete choice experiments of primary healthcare professionals. Health Economic Rev. 2020;10(1):39. doi:10.1186/s13561-020-00295-8
   PubMed Web of Science ®Google Scholar
• Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201–226.
   PubMed Web of Science ®Google Scholar
• Fifer S, Rose J, Hamrosi KK, Swain D. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Serv Res. 2018;18(1):675. doi:10.1186/s12913-018-3484-0
   PubMed Web of Science ®Google Scholar
• Fifer S, Keen B, Newton R, Puig A, McGeachie M. Understanding the treatment preferences of people living with schizophrenia in Australia: a patient value mapping study. Patient Prefer Adhe. 2022;16:1687–1701. doi:10.2147/PPA.S366522
   PubMed Web of Science ®Google Scholar
• Fifer S, Galinsky J, Richard S. Myeloma patient value mapping: a discrete choice experiment on myeloma treatment preferences in the UK. Patient Prefer Adhe. 2020;14:1283–1293. doi:10.2147/PPA.S259612
   PubMed Web of Science ®Google Scholar
• Fifer S, Puig A, Sequeira V, et al. Understanding treatment preferences of Australian patients living with treatment-resistant depression. Patient Prefer Adhe. 2021;15:1621. doi:10.2147/PPA.S311699
   PubMed Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413.
   PubMed Web of Science ®Google Scholar
• National Health and Medical Research Council; National statement on ethical conduct in human research. 2007; Available from: https://www.nhmrc.gov.au/about-us/publications/national-statement-ethical-conduct-human-research-2007-updated-2018. Accessed February 13, 2024.
   Google Scholar
• Lee PC, Dixon J. Pharmacotherapy for obesity. Aust Fam Phys. 2017;46(7):472–477.
   PubMedGoogle Scholar
• LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320(11):1172–1191. doi:10.1001/jama.2018.7777
   PubMed Web of Science ®Google Scholar
• Rose JM, Bliemer MC. Constructing efficient stated choice experimental designs. Transp Rev. 2009;29(5):587–617. doi:10.1080/01441640902827623
   Web of Science ®Google Scholar
• Hensher D, Rose J, Greene W. Applied Choice Analysis. 2nd ed. Cambridge: Cambridge University Press; 2015.
   Google Scholar
• Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient. 2019;12(3):287–295. doi:10.1007/s40271-019-00360-3
   PubMedGoogle Scholar
• Rozier MD, Ghaferi AA, Rose A, Simon NJ, Birkmeyer N, Prosser LA. Patient preferences for bariatric surgery: findings from a survey using discrete choice experiment methodology. JAMA Surg. 2019;154(1):e184375. doi:10.1001/jamasurg.2018.4375
   PubMed Web of Science ®Google Scholar
• Mansfield C, Sikirica MV, Pugh A, et al. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017;8(6):1365–1378. doi:10.1007/s13300-017-0326-8
   PubMed Web of Science ®Google Scholar
• Hyllested-Winge J, Sparre T, Pedersen LK. NovoPen Echo((R)) insulin delivery device. Med Dev. 2016;9:11–18. doi:10.2147/MDER.S59229
   Google Scholar
• Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabet Sci Technol. 2011;5(6):1563–1571. doi:10.1177/193229681100500633
   PubMedGoogle Scholar
• Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns. 2008;73(3):465–472. doi:10.1016/j.pec.2008.07.024
   PubMed Web of Science ®Google Scholar
• Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Archiv Internal Med. 2009;169(17):1560–1568. doi:10.1001/archinternmed.2009.293
   PubMedGoogle Scholar